Published in Medical Letter on the CDC and FDA, January 29th, 2006
GE Healthcare's Fast Trak BioDefense group has a staff of technical and regulatory experts who will collaborate with CytoGenix in seeking, obtaining, and executing biodefense-related federal contracts.
Frank Vazquez, CytoGenix, Inc., executive vice president and COO, commented, "Our association with GE Healthcare, a $14 billion entity of GE, as partners in competing for federal research projects sends a very positive message to grant reviewers and granting agencies at the U.S. Department of Homeland...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA